A combined nutrient and lactulose challenge test allows symptom-based clustering of patients with irritable bowel syndrome

American Journal of Gastroenterology

Volumn 108, Issue 5, 2013, Pages 786-795

  Le Neve B ^a   Posserud, I ^b   Bohn L ^b   Guyonnet, D ^a   Rondeau, P ^d   Tillisch, K ^c   Naliboff, B ^c   Mayer, E A ^c   Simren M ^b  

^a DANONE RESEARCH   (France)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Danone Research   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOHYDRATE; FAT; LACTOSE; LACTULOSE; PROTEIN;

ABDOMINAL DISCOMFORT; ABDOMINAL DISTENSION; ADULT; AGED; ANXIETY; AREA UNDER THE CURVE; ARTICLE; BLOATING; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CLUSTER ANALYSIS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; FOOD INTAKE; GLUTEN FREE DIET; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; IRRITABLE COLON; MALE; MEAL; NUTRIENT CONTENT; PILOT STUDY; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SYMPTOM;

ABDOMINAL PAIN; ADULT; AGED; ANXIETY; BREATH TESTS; CLUSTER ANALYSIS; CROSS-OVER STUDIES; DEPRESSION; DOUBLE-BLIND METHOD; FEMALE; FLATULENCE; FOOD, FORMULATED; GASTROINTESTINAL AGENTS; GASTROINTESTINAL DISEASES; HUMANS; IRRITABLE BOWEL SYNDROME; LACTULOSE; MALE; MIDDLE AGED; PILOT PROJECTS; POSTPRANDIAL PERIOD; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX;

EID: 84877583136     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2013.75     Document Type: Article

References (55)

1. Cogliandro RF, Antonucci A, De Giorgio R et al. Patient-reported outcomes and gut dysmotility in functional gastrointestinal disorders . Neurogastroenterol Motil 2011; 23: 1084-91.
2. Naliboff BD, Berman S, Suyenobu B et al. Longitudinal change in perceptual and brain activation response to visceral stimuli in irritable bowel syndrome patients . Gastroenterology 2006; 131: 352-65.
3. Azpiroz F, Bouin M, Camilleri M et al. Mechanisms of hypersensitivity in IBS and functional disorders . Neurogastroenterol Motil 2007; 19: 62-88.
4. Zhou Q, Zhang B, Nicholas Verne G . Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome . Pain 2009; 146: 41-6.
5. Posserud I, Syrous A, Lindstrom L et al. Altered rectal perception in irritable bowel syndrome is associated with symptom severity . Gastroenterology 2007; 133: 1113-23.
6. Aerssens J, Camilleri M, Talloen W et al. Alterations in mucosal immunity identifi ed in the colon of patients with irritable bowel syndrome . Clin Gastroenterol Hepatol 2008; 6: 194-205.
7. Ohman L, Simren M . Pathogenesis of IBS: role of infl ammation, immunity and neuroimmune interactions . Nat Rev Gastroenterol Hepatol 2010; 7 : 163-73.
8. Barbara G, Stanghellini V, De Giorgio R et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome . Gastroenterology 2004; 126: 693-702.
9. Coates MD, Mahoney CR, Linden DR et al. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome . Gastroenterology 2004; 126 : 1657-64.
10. Kerckhoffs APM, Ter Linde JJM, Akkermans LMA et al. SERT and TPH-1 mRNA expression are reduced in irritable bowel syndrome patients regardless of visceral sensitivity state in large intestine . Am J Physiol 2012; 302: G1053-60.
11. Dunlop SP, Hebden J, Campbell E et al. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes . Am J Gastroenterol 2006; 101: 1288-94.
12. Piche T, Barbara G, Aubert P et al. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators . Gut 2009; 58: 196-201.
13. Martinez C, Lobo B, Pigrau M et al. Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier . Gut; advance online publication, 25 May 2012; doi:10.1136/gutjnl-2012-302093.
14. Mayer EA, Tillisch K . The brain-gut axis in abdominal pain syndromes. Annu Rev Med 2011; 62: 381-96.
15. Mayer EA, Naliboff BD, Craig ADB . Neuroimaging of the brain-gut axis: from basic understanding to treatment of functional GI disorders . Gastroenterology 2006; 131: 1925-42.
16. Simren M, Barbara G, Flint HJ et al. Intestinal microbiota in functional bowel disorders: a Rome foundation report . Gut 2012; 62: 159-76.
17. Saulnier DM, Riehle K, Mistretta TA et al. Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome . Gastroenterology 2011; 141: 1782-91.
18. Kassinen A, Krogius-Kurikka L, Makivuokko H et al. The fecal microbiota of irritable bowel syndrome patients diff ers signifi cantly from that of healthy subjects . Gastroenterology 2007; 133: 24-33.
19. Matto J, Maunuksela L, Kajander K et al. Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome-a longitudinal study in IBS and control subjects . FEMS Immunol Med Microbiol 2005; 43: 213-22.
20. Noor S, Ridgway K, Scovell L et al. Ulcerative colitis and irritable bowel patients exhibit distinct abnormalities of the gut microbiota . BMC Gastroenterol 2010; 10: 134.
21. Tana C, Umesaki Y, Imaoka A et al. Altered profi les of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome . Neurogastroenterol Motil 2010; 22: 512.
22. Jeffery IB, Toole PW, Ohman L et al. An irritable bowel syndrome subtype defi ned by species-specifi c alterations in faecal microbiota . Gut 2012; 61: 997-1006.
23. Pimentel M, Park S, Mirocha J et al. The Effect of a nonabsorbed oral antibiotic (Rifaximin) on the Symptoms of the Irritable Bowel Syndrome-A Randomized Trial . Ann Intern Med 2006; 145: 557-63.
24. Pimentel M, Lembo A, Chey WD et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation . N Engl J Med 2011; 364 : 22-32.
25. Sharara AI, Aoun E, Abdul-Baki H et al. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and fl atulence . Am J Gastroenterol 2006; 101: 326-33.
26. Moayyedi P, Ford AC, Talley NJ et al. The effi cacy of probiotics in the treatment of irritable bowel syndrome: a systematic review . Gut 2010; 59: 325-32.
27. Bravo JA, Forsythe P, Chew MV et al. Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve . Proc Natl Acad Sci USA 2011; 108: 16050-5.
28. Mayer EA, Bradesi S, Chang L et al. Functional GI disorders: from animal models to drug development . Gut 2008; 57: 384-404.
29. King TS, Elia M, Hunter JO . Abnormal colonic fermentation in irritable bowel syndrome . The Lancet 1998; 352: 1187-9.
30. Serra J, Azpiroz F, Malagelada JR . Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome . Gut 2001; 48: 14-9.
31. Simren M, Agerforz P, Bjornsson ES et al. Nutrient-dependent enhancement of rectal sensitivity in irritable bowel syndrome (IBS) . Neurogastroenterol Motil 2007; 19: 20-9.
32. Ramkumar D, Rao SS . Effi cacy and safety of traditional medical therapies for chronic constipation: systematic review . Am J Gastroenterol 2005; 100: 936-71.
33. Elkington SG . Lactulose . Gut 1970; 11: 1043-8.
34. Monsbakken KW, Vandvik PO, Farup PG . Perceived food intolerance in subjects with irritable bowel syndrome-etiology, prevalence and consequences . Eur J Clin Nutr 2005; 60: 667-72.
35. Posserud I, Stotzer PO, Bjornsson ES et al. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome . Gut 2007; 56: 802-8.
36. Bratten JR, Spanier J, Jones MP . Lactulose breath testing does not discriminate patients with irritable bowel syndrome from healthy controls. Am J Gastroenterol 2008; 103: 958-63.
37. Pimentel M, Chow EJ, Lin HC . Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study . Am J Gastroenterol 2003; 98: 412-9.
38. Bouhnik Y, Neut C, Raskine L et al. Prospective, randomized, parallelgroup trial to evaluate the Effects of lactulose and polyethylene glycol-4000 on colonic fl ora in chronic idiopathic constipation . Aliment Pharmacol Ther 2004; 19: 889-99.
39. Zigmond AS, Snaith RP . The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361-70.
40. Labus JS, Bolus R, Chang L et al. The Visceral Sensitivity Index: development and validation of a gastrointestinal symptom-specifi c anxiety scale. Alimen Pharmacol Ther 2004; 20: 89-97.
41. Labus JS, Mayer EA, Chang L et al. The central role of gastrointestinalspecifi c anxiety in irritable bowel syndrome: further validation of the visceral sensitivity index . Psychosom Med 2007; 69: 89-98.
42. Jerndal P, Ringstrom G, Agerforz P et al. Gastrointestinal-specifi c anxiety: an important factor for severity of GI symptoms and quality of life in IBS. Neurogastroenterol Motil 2010; 22: 646-e179.
43. Svedlund J, Sjodin I, Dotevall G . GSRS a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease . Dig Dis Sci 1988; 33: 129-34.
44. Longstreth GF, Thompson WG, Chey WD et al. Functional bowel disorders . Gastroenterology 2006; 130: 1480-91.
45. Houghton LA, Lea R, Agrawal A et al. Relationship of abdominal bloating to distention in irritable bowel syndrome and Effect of bowel habit . Gastroenterology 2006; 131: 1003-10.
46. Bercik P, Collins SM, Verdu EF . Microbes and the gut-brain axis . Neurogastroenterol Motil 2012; 24: 405-13.
47. Messaoudi M, Violle N, Bisson JF et al. Benefi cial psychological Effects of a probiotic formulation (Lactobacillus helveticus R0052 and Bifi dobacterium longum R0175) in healthy human volunteers . Gut Microbes 2011; 2: 256-61.
48. Grover M, Kanazawa M, Palsson OS et al. Small intestinal bacterial overgrowth in irritable bowel syndrome: association with colon motility, bowel symptoms, and psychological distress . Neurogastroenterol Motil 2008; 20: 998-1008.
49. Tremolaterra F, Villoria A, Azpiroz F et al. Impaired viscerosomatic refl exes and abdominal-wall dystony associated with bloating . Gastroenterology 2006; 130: 1062-8.
50. Villoria A, Azpiroz F, Soldevilla A et al. Abdominal accommodation: a coordinated adaptation of the abdominal wall to its content . Am J Gastroenterol 2008; 103: 2807-15.
51. Burri E, Cisternas D, Villoria A et al. Accommodation of the abdomen to its content: integrated abdomino-thoracic response . Neurogastroenterol Motil 2012; 24: 312.
52. Agrawal A, Houghton LA, Lea R et al. Bloating and distention in irritable bowel syndrome: the role of visceral sensation . Gastroenterology 2008; 134: 1882-9.
53. Karaki Si, Tazoe H, Hayashi H et al. Expression of the short-chain fatty acid receptor, GPR43, in the human colon . J Mol Histol 2008; 39: 135-42.
54. Soret R, Chevalier J, De Coppet P et al. Short-chain fatty acids regulate the enteric neurons and control gastrointestinal motility in rats . Gastroenterology 2010; 138: 1772-82.
55. Simren M . Quality of life in patients with irritable bowel syndrome seen in referral centers versus primary care: the impact of gender and predominant bowel pattern . Scand J Gastroenterol 2001; 36: 545-52.